IVRI Recruiting Post Graduate degree candidates to work under the ICMR funded project
6 March 2026

IVRI Recruiting Post Graduate degree candidates to work under the ICMR funded project

Post Graduate Degree including the integrated PG degree with three years post qualification experience or PhD.
6 March 2026
Biotechnology Fellowship in the Systems Biology for Biofuel Group, ICGEB
The incumbent should have an M.Sc. in Natural/ Agricultural Sciences/ Biotechnology or a Bachelor’s degree in Engineering or Technology from a recognized University or equivalent.
6 March 2026
Applications are invited for post of Liaison Officer at NIMS
Pharm.D (Pg course). The application should be submitted in the enclosed format and must be accompanied by attested copies of certificates in support of all information furnished in the application.
6 March 2026
Fresher Production / QA / QC Openings at Macleods
Macleods is one of the fastest growing pharmaceutical company, having strong presence in various therapeutics segments. Ranked amongst the top 10 companies.
6 March 2026
Call for Research Associate Position at Alembic Pharma - Pharma apply
Review and provide technical inputs on Product Development Reports, Master Formula Cards, and Technology Transfer documents
6 March 2026
Ipca Laboratories expands in Quality Control
Experience in Review of Data, Audit Tail Review and Release, OOS, 00T, LIR, Empower, LIMS
6 March 2026
Hiring for Quality Assurance at Amneal Pharma
Real-time review of BMR / BPRs, aseptic interventions, filtration integrity incl. PUPSIT where applicable), lyophilization & visual inspection processes.
6 March 2026
Production and Packing Jobs at Ipca Laboratories
Ipca Laboratories Ltd. has launched its Centre of Excellence (CoE) - a specialized training initiative aimed at providing hands-on industrial exposure to students aspiring to build a career in the pharmaceutical industry.
6 March 2026
AQA Formulation, QA Jobs at Bioplus
Experience in RM & PM analysis and document review with expertise in analytical techniques (HPLC, GC, UV, Dissolution), method validation, and regulatory compliance
6 March 2026
FDA Approves New Combination Therapy for Relapsed or Refractory Multiple Myeloma

The U.S. Food and Drug Administration has approved a new treatment combination of teclistamab‑cqyv with daratumumab and hyaluronidase‑fihj for adult patients with relapsed or refractory Multiple Myeloma. The approval offers a new therapeutic option for patients whose disease has returned or stopped responding after earlier treatments.